Patents by Inventor Dae Ryoung Park

Dae Ryoung Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of cADPR or NAADP antagonists
    Patent number: 11071748
    Abstract: When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 27, 2021
    Assignee: Industrial Cooperation Foundation Chonbuk National University
    Inventors: Uh Hyun Kim, Dae Ryoung Park, Kwang Hyun Park
  • USE OF cADPR OR NAADP ANTAGONISTS
    Publication number: 20200046750
    Abstract: When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 13, 2020
    Inventors: Uh Hyun Kim, Dae Ryoung Park, Kwang Hyun Park